Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF, Sporn MB. Veronesi U, et al. Among authors: di mauro mg. J Natl Cancer Inst. 1999 Nov 3;91(21):1847-56. doi: 10.1093/jnci/91.21.1847. J Natl Cancer Inst. 1999. PMID: 10547391 Clinical Trial.
Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F. Decensi A, et al. Among authors: di mauro mg. Clin Cancer Res. 2003 Oct 15;9(13):4722-9. Clin Cancer Res. 2003. PMID: 14581342 Clinical Trial.
Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N, De Palo G, Formelli F, Costa A, Marubini E, Campa T, Crippa A, Danesini GM, Delle Grottaglie M, Di Mauro MG, et al. Rotmensz N, et al. Among authors: di mauro mg. Eur J Cancer. 1991;27(9):1127-31. doi: 10.1016/0277-5379(91)90309-2. Eur J Cancer. 1991. PMID: 1835622 Clinical Trial.
Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
De Palo G, Camerini T, Marubini E, Costa A, Formelli F, Del Vecchio M, Mariani L, Miceli R, Mascotti G, Magni A, Campa T, Di Mauro MG, Attili A, Maltoni C, Del Turco MR, Decensi A, D'Aiuto G, Veronesi U. De Palo G, et al. Among authors: di mauro mg. Tumori. 1997 Nov-Dec;83(6):884-94. doi: 10.1177/030089169708300603. Tumori. 1997. PMID: 9526578 Clinical Trial.
Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
Decensi A, Johansson H, Miceli R, Mariani L, Camerini T, Cavadini E, Di Mauro MG, Barreca A, Gonzaga AG, Diani S, Sandri MT, De Palo G, Formelli F. Decensi A, et al. Among authors: di mauro mg. Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1047-53. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11588130 Clinical Trial.
Plasma retinol and prognosis of postmenopausal breast cancer patients.
Formelli F, Meneghini E, Cavadini E, Camerini T, Di Mauro MG, De Palo G, Veronesi U, Berrino F, Micheli A. Formelli F, et al. Among authors: di mauro mg. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):42-8. doi: 10.1158/1055-9965.EPI-08-0496. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19124479
23 results